Jacob Vincent Micallef Buys 50,000 Shares of VolitionRx Limited (NYSE:VNRX) Stock

VolitionRx Limited (NYSE:VNRX) insider Jacob Vincent Micallef purchased 50,000 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were purchased at an average price of $0.43 per share, for a total transaction of $21,500.00. Following the completion of the purchase, the insider now directly owns 426,033 shares of the company’s stock, valued at approximately $183,194.19. This trade represents a 13.30% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

VolitionRx Trading Up 17.1%

VNRX stock opened at $0.49 on Wednesday. VolitionRx Limited has a 1-year low of $0.40 and a 1-year high of $0.90. The firm has a market cap of $49.48 million, a P/E ratio of -1.36 and a beta of 1.00. The business’s 50 day moving average is $0.50 and its 200-day moving average is $0.59.

Institutional Investors Weigh In On VolitionRx

Large investors have recently modified their holdings of the stock. Lagoda Investment Management L.P. grew its stake in shares of VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the period. Two Sigma Securities LLC bought a new stake in shares of VolitionRx in the 4th quarter valued at approximately $29,000. Millennium Management LLC bought a new stake in shares of VolitionRx in the 4th quarter valued at approximately $36,000. Finally, Northern Trust Corp grew its stake in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the period. 8.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

VNRX has been the topic of several research reports. D. Boral Capital restated a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research note on Wednesday, April 30th. HC Wainwright initiated coverage on VolitionRx in a research note on Tuesday, April 8th. They set a “buy” rating and a $2.50 price target on the stock. Finally, StockNews.com began coverage on VolitionRx in a research note on Thursday, May 15th. They set a “sell” rating on the stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.